Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)

Farshid Dayyani, Carol J Etzel, Mei Liu, Chung-Han Ho, Scott M Lippman, Anne S Tsao, Farshid Dayyani, Carol J Etzel, Mei Liu, Chung-Han Ho, Scott M Lippman, Anne S Tsao

Abstract

Background: HPV is important in a subset of HNSCC. Our meta-analysis determined the clinical characteristics of HPV-related HNSCC.

Method: Pubmed search terms "HPV" and "HNSCC" were used to identify 34 studies since 1980. We obtained pooled adjusted odds ratio (OR) or hazard ratio (HR) using random or fixed-effects model and compared OS depicted in forest plot.

Results: A total of 5681 patients were included. The prevalence of HPV+ tumors was 22%, with 86.7% of HPV16+ genotype. The OR for HNSCC in HPV16+ patients was 4.44 (95% CI = 2.87-6.02). HPV status was associated with p16 expression (adj OR = 3.00; 0.90-9.70), and HPV+ tumors were less likely to harbor p53 mutations (adj OR = 0.21; 0.04-0.38). The HR for death in HPV+ patients was 0.42 (0.27-0.57). HPV+ HNSCC also had a better response to therapy.

Conclusion: HPV+ HNSCC are established as a separate biologic entity. Prospective trials are needed to establish the optimal therapy for HPV+ HNSCC.

Figures

Figure 1
Figure 1
Meta-analyses for adjusted odds ratio (OR) for HPV as risk factor for HNSCC Risk for having HNSCC is increased with all types of high-risk HPV reported (A) and risk is even more pronounced in cases with HPV-16 infection versus HPV negative controls (B).
Figure 2
Figure 2
Overall survival of HPV positive patients compared to HPV negative patients in unselected HNSCC patients (A) and in the subgroup of patients with oropharyngeal cancers (B).

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008;58(2):71–96. doi: 10.3322/CA.2007.0010.
    1. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer. 2005;103(9):1843–1849. doi: 10.1002/cncr.20998.
    1. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W, Dalianis T. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. International journal of cancer. 2006;119(11):2620–2623. doi: 10.1002/ijc.22177.
    1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature reviews. 2002;2(5):342–350. doi: 10.1038/nrc798.
    1. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. Case-control study of human papillomavirus and oropharyngeal cancer. The New England journal of medicine. 2007;356(19):1944–1956. doi: 10.1056/NEJMoa065497.
    1. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute. 2000;92(9):709–720. doi: 10.1093/jnci/92.9.709.
    1. Gillison ML, Shah KV. Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Current opinion in oncology. 2001;13(3):183–188. doi: 10.1097/00001622-200105000-00009.
    1. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. Journal of the National Cancer Institute. 2008;100(6):407–420. doi: 10.1093/jnci/djn025.
    1. Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer research. 1998;58(1):5–13.
    1. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute. 2008;100(4):261–269. doi: 10.1093/jnci/djn011.
    1. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (New York, NY) 1989;243(4893):934–937.
    1. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (New York, NY) 1990;248(4951):76–79.
    1. Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2008;14(2):366–369. doi: 10.1158/1078-0432.CCR-07-1402.
    1. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26(19):3128–3137. doi: 10.1200/JCO.2007.12.7662.
    1. O'Regan EM, Toner ME, Finn SP, Fan CY, Ring M, Hagmar B, Timon C, Smyth P, Cahill S, Flavin R. p16(INK4A) genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. Human pathology. 2008;39(3):452–458. doi: 10.1016/j.humpath.2007.08.004.
    1. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24(5):736–747. doi: 10.1200/JCO.2004.00.3335.
    1. Mroz EA, Baird AH, Michaud WA, Rocco JW. COOH-terminal binding protein regulates expression of the p16INK4A tumor suppressor and senescence in primary human cells. Cancer research. 2008;68(15):6049–6053. doi: 10.1158/0008-5472.CAN-08-1279.
    1. Nichols AC, Faquin WC, Westra WH, Mroz EA, Begum S, Clark JR, Rocco JW. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2009;140(2):228–234. doi: 10.1016/j.otohns.2008.11.025.
    1. Gillison HJ ML, Westra W, Chung C, Jordan R, Rosenthal D, Nguyen-Tan P, Spanos WJ, Redmond KP, Ang K. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol. 2009;27:15s. doi: 10.1200/JCO.2008.21.7695.
    1. Murata M, Takayama K, Choi BC, Pak AW. A nested case-control study on alcohol drinking, tobacco smoking, and cancer. Cancer detection and prevention. 1996;20(6):557–565.
    1. Spitz MR. Epidemiology and risk factors for head and neck cancer. Seminars in oncology. 1994;21(3):281–288.
    1. Charfi L, Jouffroy T, de Cremoux P, Le Peltier N, Thioux M, Freneaux P, Point D, Girod A, Rodriguez J, Sastre-Garau X. Two types of squamous cell carcinoma of the palatine tonsil characterized by distinct etiology, molecular features and outcome. Cancer letters. 2008;260(1-2):72–78. doi: 10.1016/j.canlet.2007.10.028.
    1. Hafkamp HC, Manni JJ, Haesevoets A, Voogd AC, Schepers M, Bot FJ, Hopman AH, Ramaekers FC, Speel EJ. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. International journal of cancer. 2008;122(12):2656–2664. doi: 10.1002/ijc.23458.
    1. Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantu G, Squadrelli M. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006;24(36):5630–5636. doi: 10.1200/JCO.2005.04.6136.
    1. Ragin CC, Taioli E, Weissfeld JL, White JS, Rossie KM, Modugno F, Gollin SM. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. British journal of cancer. 2006;95(10):1432–1438. doi: 10.1038/sj.bjc.6603394.
    1. Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK, Speel EJ, Dienes HP, Pfister HJ, Guntinas-Lichius O. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. International journal of cancer. 2007;120(8):1731–1738. doi: 10.1002/ijc.22355.
    1. Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, Shyr Y, Murphy BM, Cmelak AJ, Burkey BB. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12(3 Pt 1):701–709. doi: 10.1158/1078-0432.CCR-05-2017.
    1. Smith EM, Wang D, Kim Y, Rubenstein LM, Lee JH, Haugen TH, Turek LP. P16INK4a expression, human papillomavirus, and survival in head and neck cancer. Oral oncology. 2008;44(2):133–142. doi: 10.1016/j.oraloncology.2007.01.010.
    1. Wittekindt C, Gultekin E, Weissenborn SJ, Dienes HP, Pfister HJ, Klussmann JP. Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Advances in oto-rhino-laryngology. 2005;62:72–80.
    1. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467–475. doi: 10.1158/1055-9965.EPI-04-0551.
    1. Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, Campisi G. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007) Ann Oncol. 2008;19(10):1681–1690. doi: 10.1093/annonc/mdn372.
    1. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. International journal of cancer. 2007;121(8):1813–1820. doi: 10.1002/ijc.22851.
    1. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol. 2006;31(4):259–266. doi: 10.1111/j.1749-4486.2006.01246.x.
    1. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer research. 1994;54(23):6078–6082.
    1. Klussmann JP, Gultekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, Eckel HE, Pfister HJ, Fuchs PG. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. The American journal of pathology. 2003;162(3):747–753.
    1. Li W, Thompson CH, Cossart YE, O'Brien CJ, McNeil EB, Scolyer RA, Rose BR. The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head & neck. 2004;26(1):1–9. doi: 10.1002/hed.10335.
    1. Rischin DYR, Fisher R, Fox S, Le Q, Peters L, Choi J, O'Sullivan B, Giralt J, McArthur G. Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. J Clin Oncol. 2009;27:15s. doi: 10.1200/JCO.2008.21.7695.
    1. Campisi G, Giovannelli L. Controversies surrounding Human Papilloma Virus infection, head & neck vs oral cancer, implications for prophylaxis and treatment. Head & neck oncology. 2009;1(1):8. doi: 10.1186/1758-3284-1-8.
    1. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-Associated p16INK4A Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of the Head and Neck. J Clin Oncol. 2009;27(12):1992–8. doi: 10.1200/JCO.2008.20.2853.
    1. Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, Wolf GT, Urba SG, Worden FP, Chepeha DB, Teknos TN. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. International journal of radiation oncology, biology, physics. 2007;69(2 Suppl):S109–111.
    1. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008;26(19):3138–3146. doi: 10.1200/JCO.2007.12.7597.
    1. Cohen MA, Basha SR, Reichenbach DK, Robertson E, Sewell DA. Increased viral load correlates with improved survival in HPV-16-associated tonsil carcinoma patients. Acta oto-laryngologica. 2008;128(5):583–589. doi: 10.1080/00016480701558880.
    1. Worden HJ FP, Lee J, Eisbruch A, Wolf GT, Prince M, Moyer J, Teknos T, Chepeha DB, Bradford CR, Carey T. Association of tobacco (T) use with risk of distant metastases (DM), tumor recurrence, and death in patients (pts) with HPV-positive (+) squamous cell cancer of the oropharynx (SCCOP) J Clin Oncol. 2009;27:15s. doi: 10.1200/JCO.2008.21.7695.
    1. Tran N, Rose BR, O'Brien CJ. Role of human papillomavirus in the etiology of head and neck cancer. Head & neck. 2007;29(1):64–70. doi: 10.1002/hed.20460.
    1. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The New England journal of medicine. 2007;356(19):1915–1927. doi: 10.1056/NEJMoa061741.
    1. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161–2170. doi: 10.1016/S0140-6736(07)60946-5.
    1. Chang Y, Brewer NT, Rinas AC, Schmitt K, Smith JS. Evaluating the impact of human papillomavirus vaccines. Vaccine. 2009;27(32):4355–4362. doi: 10.1016/j.vaccine.2009.03.008.
    1. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ (Clinical research ed) 2009;339:b3884. doi: 10.1136/bmj.b3884.
    1. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Annals of internal medicine. 2009;151(8):538–545.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner